#### Sex-specific differences in physiological parameters related to 1 SARS-CoV-2 infections among a national cohort (COVI-GAPP 2 study) 3

- 4 Kirsten Grossmann<sup>1,2</sup>¶, Martin Risch<sup>2,3,4</sup>¶, Andjela Markovic<sup>5,6,7</sup>¶, Stefanie Aeschbacher<sup>8</sup>, Ornella C
- 5 Weideli<sup>2,9</sup>, Laura Velez<sup>2</sup>, Marc Kovac<sup>4</sup>, Fiona Pereira<sup>10</sup>, Nadia Wohlwend<sup>4</sup>, Corina Risch<sup>4</sup>, Dorothea
- Hillmann<sup>4</sup>, Thomas Lung<sup>4</sup>, Harald Renz<sup>11</sup>, Raphael Twerenbold<sup>8,12</sup>, Martina Rothenbühler<sup>5</sup>, Daniel 6
- 7 Leibovitz<sup>5</sup>, Vladimir Kovacevic<sup>5</sup>, Paul Klaver<sup>13</sup>, Timo B Brakenhoff<sup>13</sup>, Billy Franks<sup>13</sup>, Marianna
- Mitratza<sup>14,15</sup>, George S Downward<sup>14,15</sup>, Ariel Dowling<sup>16</sup>, Santiago Montes<sup>17</sup>, Duco Veen<sup>18,19</sup>, Diederick 8
- E Grobbee<sup>14,15&</sup>, Maureen Cronin<sup>5&</sup>, David Conen<sup>20&</sup>, Brianna M Goodale<sup>5,12&</sup>, Lorenz Risch<sup>1,2,4,21&\*</sup>, on 9
- 10 behalf of the COVID-19 remote early detection (COVID-RED) consortium<sup>^</sup>
- 11 <sup>+</sup>Full list of group members is provided in the Appendix
- 12

13 <sup>1</sup>Private University in the Principality of Liechtenstein (UFL), Triesen, Principality of Liechtenstein

- 14 <sup>2</sup> Dr Risch Medical Laboratory, Vaduz, Liechtenstein
- 15 <sup>3</sup> Central Laboratory, Kantonsspital Graubünden, Chur, Switzerland
- 16 <sup>4</sup> Dr Risch Medical Laboratory, Buchs, Switzerland
- 17 <sup>5</sup>Ava AG, Zürich, Switzerland
- 18 <sup>6</sup>Department of Psychology, University of Fribourg, Fribourg, Switzerland
- 19 <sup>7</sup>Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland
- 20 <sup>8</sup> Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Basel, Switzerland
- 21 <sup>9</sup>Soneva Fushi, Boduthakurufaanu Magu, Male, Maldives
- 22 <sup>10</sup> Department of Metabolism, Digestive Diseases and Reproduction, Imperial College London, South Kensington Campus, London, 23 UK
- 24 <sup>11</sup> Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, Marburg, Germany
- 25 <sup>12</sup> Department of Cardiology and University Center of Cardiovascular Science, University Heart and Vascular Center Hamburg, 26 Hamburg, Germany
- 27 <sup>13</sup> Julius Clinical, Zeist, The Netherlands
- 28 <sup>14</sup> UMC Utrecht, Utrecht, The Netherlands
- 29 <sup>15</sup> Julius Global Health, the Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The 30 Netherlands
- 31 <sup>16</sup> Takeda Pharmaceuticals, Digital Clinical Devices, Cambridge, Massachusetts, USA
- 32 <sup>17</sup> Roche Diagnostics Nederland B.V., Almere, The Netherlands
- 33 <sup>18</sup>Department of Methodology and Statistics, Utrecht University, Utrecht, The Netherlands
- 34 <sup>19</sup>Optentia Research Programme, North-West University, South Africa
- 35 <sup>20</sup> Population Health Research Institute, McMaster University, Hamilton, Canada
- 36 <sup>21</sup> Center of Laboratory Medicine, University Institute of Clinical Chemistry, University of Bern, Inselspital, Bern, Switzerland
- 37 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 38

P	orporany		
It is made available under	a CC-BY	Y 4.0 International license	

39	
40 41	&These authors also contributed equally to this work.
42	*Corresponding author
43	Email: <u>lorenz.risch@ufli.li (LR)</u>
44	^Membership of the COVID-RED consortium is provided in the Appendix.
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	

## 62 Abstract

63

Considering sex as a biological variable in modern digital health solutions, we investigated sex-specific
 differences in the trajectory of four physiological parameters across a COVID-19 infection.

A wearable medical device measured breathing rate, heart rate, heart rate variability, and wrist skin temperature in 1163 participants (mean age = 44.1 years, standard deviation [SD]=5.6; 667 [57%] females). Participants reported daily symptoms and confounders in a complementary app. A machine learning algorithm retrospectively ingested daily biophysical parameters to detect COVID-19 infections. COVID-19 serology samples were collected from all participants at baseline and follow-up. We analysed potential sex-specific differences in physiology and antibody titres using multilevel modelling and t-tests.

Over 1.5 million hours of physiological data were recorded. During the symptomatic period of infection, men demonstrated larger increases in skin temperature, breathing rate and heart rate as well as larger decreases in heart rate variability than women. The COVID-19 infection detection algorithm performed similarly well for men and women.

Our study belongs to the first research to provide evidence for differential physiological responses to
 COVID-19 between females and males, highlighting the potential of wearable technology to inform
 future precision medicine approaches.

This work has received support from the Princely House of the Principality of Liechtenstein, the government of the Principality of Liechtenstein, the Hanela Foundation in Switzerland, and the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant agreement No 101005177. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

## 85 Introduction

86

87 On March 11, 2020, the WHO declared the fast spreading coronavirus disease (COVID-19) a global 88 pandemic [1]. This novel viral disease was first detected in Wuhan, China in December 2019 and is 89 caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) [2]. Increasing knowledge 90 about risk factors and symptoms, as well as the implementation of mass reverse transcription 91 polymerase chain reaction (RT-PCR), serological tests, vaccines and social restrictions have helped 92 control its spread [3,4]. However, asymptomatic virus transmissions and emerging virus mutations 93 pose ongoing challenges in dealing with the pandemic. Today, more than two years after the first case 94 was detected, many countries worldwide continue to experience waves of rising infections, with 95 numerous unknowns remaining in our understanding of SARS-CoV-2. In particular, consistent data 96 about the role of sex in relation to COVID-19 are lacking [5,6]. Significant changes in physiological 97 parameters as breathing rate, heart rate, heart rate variability, and wrist skin temperature during a 98 COVID-19 infection [7] raise the question about sex-specific differences within the trajectory of these 99 parameters. A better understanding of sex-specific trajectories in physiological responses to the 100 infection may support early detection and treatment of COVID-19.

101

102 A meta-analysis found that men with COVID-19 were globally almost three times more likely than 103 women to be admitted to an intensive treatment unit [8]. Furthermore, the disease's mortality rates 104 were higher in men [9], potentially due to sex-specific differences in angiotensin converting enzyme 2 105 (ACE2) expression [10,11]. On the other hand, women were found to more frequently experience 106 persistent symptoms such as dyspnoea and fatigue several months after the acute phase of the illness 107 [12]. The infection rates were similar between the sexes [8], although this observation may differ 108 between countries [13]. Moreover, initial analyses of eumenorrheic women's susceptibility to SARS-109 CoV-2 among a real-world sample are in line with previously shown immune function fluctuations 110 across the menstrual cycle [14] and suggest increased susceptibility during the luteal phase [15]. 111 Research on sex-specific differences in immune responses that underlie COVID-19 disease outcomes

showed higher plasma levels of innate immune cytokines such as IL-8 and IL-18 along with more robust induction of non-classical monocytes in male patients, whereas female patients showed higher T cell activation during SARS-CoV-2 infection [16]. Also, higher levels of innate immune cytokines were associated with worse disease progression in female patients [16].

116

117 To the best of our knowledge, our work represents the first investigation of sex-specific differences in 118 SARS-CoV-2 affected physiological parameters as measured by a medical device. Previous studies have 119 shown that direct-to-consumer and easy to use products with wide market availability such as Fitbit 120 [17], smartwatches [18], the Ava bracelet [7,19], and other wearable devices [20] could be used for 121 surveillance of changes in physiological parameters to give the user an early warning before COVID-122 19 symptom occurrence [21] or during asymptomatic infection [22]. The COVI-GAPP study 123 investigated the applicability of the Ava bracelet for pre-symptomatic detection of COVID-19 [23]. 124 Developed as a fertility tracker, the bracelet measures physiological parameters including wrist skin 125 temperature, breathing rate, heart rate, heart rate variability and skin perfusion [24]. The previously 126 published interim analysis of the COVI-GAPP dataset demonstrated significant changes in skin 127 temperature, breathing rate, heart rate and heart rate variability during a COVID-19 infection [7]. These parameters were used to develop a machine learning (ML) algorithm for detection of pre-128 129 symptomatic SARS-CoV-2 infection which successfully detected 68% of COVID-19 cases up to two days 130 before symptom onset. The algorithm is currently being tested and validated in a larger population 131 with real-time access to the algorithm's predictions [19].

132

The current work analyzed the same physiological parameters collected in the COVI-GAPP study to quantify sex-specific differences before, during and after a COVID-19 infection. We examined differences in trajectories of physiological parameters over five defined phases (baseline, incubation, pre-symptomatic, symptomatic, recovery) between female and male participants. Furthermore, we evaluated the performance of our ML algorithm for female and male participants separately with the

138	goal	to	assess	and	correct	а	potential	sex	bias	in	its	functionality.

#### Materials and Methods 139

#### Study design and participants 140

142 Since 2010, the observational population-based Genetic and Phenotypic Determinants of Blood 143 Pressure and Other Cardiovascular Risk Factors (GAPP) study aims to better understand the 144 development of cardiovascular risk factors in the general population of healthy adults aged 25 to 41 years [25]. From 2170 GAPP participants, 1163 individuals were enrolled in the COVI-GAPP study with 145 inclusion and exclusion criteria published previously [23]. Data were collected from April 14, 2020, 146 147 until January 31, 2022. The local ethics committee (KEK, Zürich, Switzerland) approved the study 148 protocol, and written informed consent was obtained from each participant prior to enrolment (BASEC 2020-00786). 149

#### Data collection 150

151

141

### Physiological parameters of interest for this analysis were breathing rate, heart rate, heart rate 152 153 variability, and wrist skin temperature, measured every 10 seconds by a wrist-worn bracelet while the 154 user slept. The CE-certified and FDA-cleared Ava Fertility Tracker (version 2.0; Ava AG, Switzerland) was originally built to detect ovulating women's fertile days in real time with 90% accuracy [26–28]. 155 The bracelet's three sensors can track biophysical changes regardless of the wearer's sex [7] and was 156 157 used in this study for detecting infection-based deviations from baseline parameters in both men and 158 women (regardless of their menstruating status). Participants synchronized their bracelet each 159 morning upon waking to a complementary smartphone app.

160 In addition to automatically collected physiological data, participants also provided information in the 161 complementary app about their daily alcohol, medication, and drug intake (Fig 1A), as these 162 substances can alter central nervous system functioning [29]. Furthermore, the app included a customized user functionality where participants reported COVID-19 symptoms in a daily diary (Fig 163

164 1B). Participants were also able to see and monitor changes in their physiological parameters in the app.

165

171

#### 166 This is the Fig 1A and Fig 1B Title. Participants wore a wrist-based medical device at night.

167 This is the Fig 1A and Fig 1B legend. Upon waking, participants synchronized the device with a 168 complementary smartphone application and reported alcohol, medication, and drug intake (A) as well 169 as potential COVID-19 symptoms (B) in the app.

#### SARS-CoV-2 antibody testing and RT-PCR testing 170

172 SARS-CoV-2 antibody tests were performed by the medical laboratory Dr Risch Ostschweiz AG (Buchs 173 SG, Switzerland) with an orthogonal test algorithm employing electrochemiluminescence (ECLIA) 174 assays testing for pan-immunoglobulins directed against the N antigen and the receptor binding 175 domain (RBD) of the SARS-CoV-2 spike protein, as described by Risch et al [30]. The enacted procedure 176 ensures testing for actual SARS-CoV-2 infection independent of vaccine status. Baseline data were 177 collected starting in April 2020 onwards (run 1; R1). Three follow-up blood samples (run 2, R2; run 3, 178 R3; and run 4, R4) were collected within the scope of the study (Fig 2). The cut-off levels used for 179 positive and negative values were  $\geq$  1.0 and  $\leq$  0.1, respectively. Values between 0.2 – 0.9 were 180 considered as gray zone. Seroconversion was assumed if the first blood sample was negative for SARS-181 CoV-2 antibodies, but a subsequent sample was positive. Follow-up calls with participants who tested 182 positive were performed to discuss their symptoms and duration.

183 This is the Fig 2 Titel. Study flow chart of the 1,163 participants that are enrolled in the COVI-GAPP 184 study.

185 This is the Fig 2 legend. The cut-off levels used for positive and negative values were  $\geq$  1.0 and  $\leq$  0.1, 186 respectively. Values between 0.2 - 0.9 were considered as gray zone \* Successful bracelet 187 synchronization on more than 50% of days around symptom onset.

188

189

## 190 Questionnaires

191

When visiting the study centre for SARS-CoV-2 antibody tests, participants were asked to answer a questionnaire about their personal information (age, sex), smoking status (current, past, never), as well as symptoms and hospitalizations during COVID-19 infection. Body mass index (BMI) based on height and weights were calculated with data from the GAPP database.

## 196 Statistical Analysis

Our primary objective was to examine sex differences in the trajectory of breathing rate, heart rate, heart rate variability, and wrist skin temperature across a SARS-CoV-2 infection. Secondarily, we evaluated a machine learning algorithm designed for early detection of COVID-19 separately in male and female participants to examine potential sex biases in algorithm performance. Furthermore, we assessed sex-specific differences in antibody titres after SARS-CoV-2 infections. We processed and analysed all data using R (version 4.1.1) [31] and Python (version 3.6) [32].

### 1. Sex-specific differences in COVID-19 related physiological parameters

205 To examine the association between sex and physiological parameters during baseline, incubation, 206 pre-symptomatic, symptomatic and recovery phases of a COVID-19 infection, we applied multilevel 207 linear mixed models with random intercepts and slopes including residual maximum likelihood 208 estimation (REML) and Satterthwaite degrees of freedom. A multiplicative interaction term tested the 209 association between sex and infection phase. All signals measured more than 10 days before symptom 210 onset via phone call confirmation with a study team member were categorized as occurring during 211 the baseline period. The incubation period was defined as the time interval from 10 days up to 3 days 212 before symptom onset. The pre-symptomatic period was defined as the two days before symptom 213 onset, while the symptomatic period lasted from the day of symptom onset until the day symptoms 214 ended. All signals measured after symptom end were categorized as occurring during the recovery 215 period. We dummy coded four variables to indicate the period within which the signal occurred, with

baseline serving as the reference period. Each of the four multilevel models was compared to thecorresponding null model (i.e., an intercept-only model) by means of an ANOVA.

218

As a sensitivity analysis, we also tested potentially confounding variables as single terms in additional models to determine whether changes in physiological parameters occurred due to COVID-19 infection over and above changes associated with participant age, BMI, hypertension, medication, alcohol, and recreational drugs.

### 223 2. Sex-specific differences in algorithm's performance

224 The retrospective ML algorithm, developed as described in previous papers, [7,19] aimed to detect a 225 COVID-19 infection prior to symptom onset. The algorithm was designed to ingest trends in 226 physiological signals across sets of days to detect deviations in these signals and predict a potential 227 infection. The model was trained to predict infection two days and one day prior to symptom onset, 228 as well as on the day of symptom onset. Here, we assessed the algorithm's performance metrics 229 separately for male and female COVI-GAPP participants to identify any potential sex bias in the model. 230 Performance metrics were calculated per day in participants who tested positive where days from -40 231 to -2 relative to the onset of the first symptoms were considered negative and days -2 to day 0 as 232 positive. In other words, positive predictions of the algorithm prior to 2 days before symptom onset, 233 these predictions were interpreted as false positives. The set of metrics selected for the evaluation of 234 the algorithm included precision (number of true positives divided by sum of true positives and false

positives), recall (number of true positives divided by the sum of true positives and false negatives),

and F-score (the harmonic mean of precision and recall).

### 3. Sex-specific differences in antibody titres of SARS-CoV-2 Nucleocapsid

- after COVID-19 infection
- 239 To enable a reliable comparison of antibody titres after a COVID-19 infection, antibody titres (values

240 > 1.0) against the SARS-CoV-2 Nucleocapsid were compared between sex. Blood was collected four

- times over the course of the study with varying sample sizes (Fig 2). Normally distributed continuous
- 242 variables were compared using unpaired t-tests, and non-parametric continuous variables were
- 243 compared using Mann-Whitney U tests.

244

## 245 **Results**

246

### 247 Participants

248 A total of 1163 participants (mean age = 44.1 years, standard deviation [SD] = 5.6; 667 [57%] females) 249 250 were enrolled in the study. During the study period, 127 participants (10.9%; [9.3,12.8]) contracted 251 COVID-19. Eighty-two participants (mean age =  $42.6 \pm 5.3$  years; 56 [68%] females) testing positive for 252 SARS-CoV-2 had worn and synchronized their bracelet successfully on more than 50% of days around 253 symptom onset (i.e., at least 20 days before and 20 days after symptom onset), thereby ensuring 254 sufficient quality of data to be included in analyses. The number of days with successfully synchronized 255 bracelet data did not differ (p = 0.967) between females (range 67 to 511 days; mean = 239.6 ± 71.8 256 days) and males (range 45 to 508 days; mean =  $238.8 \pm 86.4$  days). With regards to the reported 257 symptom duration, values for four participants (2 females) were missing and imputed based on the 258 median across the sample.

Blood samples and questionnaire data were available from 1,144 participants. Mean age and BMI of these participants were 45 (± 5.5) and 24.7 (± 3.9), respectively. At baseline, male participants had significantly higher BMIs (26.17 ± 3.41) than female participants (23.70 ± 3.96; t(1079) = 10.71, p<0.001). They also reported significantly higher rates of hypertension (7.74%) than female participants (3.15%;  $X^2(1) = 11.23$ , p<0.001). Analyses did not reveal any significant sex-based differences in smoking status, age, or hospitalization rate (Table 1).

#### 265 Table 1. This is the Table 1 Title. Baseline characteristics stratified according to sex were collected

Variables	Total n = 1,144	Male n = 478	Female n = 666	Test statistics	Significance (p value)
Smoking status, N (never: current: past smoker)	658: 167: 319	265: 68: 145	393: 99: 174	X2 (2) = 2.46	0.292
Hypertension, N (yes: no)	58: 1086	37: 441	21: 645	X2 (1) = 11.23	<0.001
Age, years (±SD)	43.99 (± 5.51)	44.3 (±5.35)	43.77 (±5.61)	t (1057) = 1.53	0.1449
BMI, kg/m2 (±SD)	24.72 (±3.94)	26.17 (±3.41)	23.7 (±3.96)	t (1079) = 10.71	<0.001
Hospitalization 01, N (yes: no)	0:10	0:4	0:6	Fisher's exact test	1
Hospitalization 02, N (yes: no)	11:113	7:44	4:69	X2 (1) = 2.52	0.2047
Hospitalization 03, N (yes: no)	2:23	0:12	2:11	X2 (1) = 0.46	0.4973
Hospitalization 04, N (yes: no)	3:47	0:24	3:23	X2 (1) = 1.25	0.2625

#### 266 by questionnaires completed within the GAPP study.

This is the Table 1 legend. Information about hospitalization were collected 4 times (01 - 04) as part 268 of a questionnaire for SARS-CoV-2 positive participants within the COVI-GAPP study. Data are 269 270 presented as mean ± SD, or number.

#### Sex-specific differences in COVID-19 related physiological parameters 271

272 We show the trajectory each of the four analysed physiological parameters during a SARS-CoV-2 273 infection separated by sex (Fig 3). The multilevel models revealed significant differences between male 274 and female participants in all parameters during the symptomatic period (Table 2). We observed a 275 larger increase in skin temperature, breathing rate and heart rate as well as a larger decrease in heart rate variability in males compared to females during this period. Moreover, male participants' 276 277 breathing rate and heart rate remained at significantly higher levels during the recovery period as 278 compared to their female peers (Table 2). Each of the four models provided a significantly better fit 279 to the data than the corresponding null model (p<0.0001).

280

<sup>267</sup> 

### 281 This is the Fig 3 Title. Trajectory of the four analysed physiological parameters across the course of

### a confirmed COVID-19 infection, centred around participant-reported symptom onset.

- 283 This is the Fig 3 legend. The values of each physiological parameter (with 95% CIs) were normalized
- according to each individual's baseline measurements and collapsed across females (n=56) and males
- 285 (n=26).
- 286

### 287 Table 2. This is the Table 2 Title. Results from multilevel linear mixed models showing the main

- 288 effects of infection phase and sex as well as the interactions between the two with regards to
- 289 changes in physiological signals.

	Skin temperature	Breathing rate	Heart rate	Heart rate
				variability
Intercept	35.01 (<0.0001)	13.51 (<0.0001)	46.98 (<0.0001)	4.3 (<0.0001)
Infection phase				
Baseline	Reference	Reference	Reference	Reference
Incubation	0.18 (0.15)	0.33 (0.13)	1.49 (0.12)	-0.25 (0.12)
Pre-symptomatic	0.23 (0.26)	0.71 (0.17)	1.26 (0.41)	-0.18 (0.42)
Symptomatic	0.74 (<0.0001)	2.93 (<0.0001)	6.88 (<0.0001)	-0.93 (<0.0001)
Recovery	0.22 (0.0006)	0.38 (0.004)	2.17 (0.003)	-0.28 (0.09)
Sex, female	0.45 (<0.0001)	0.91 (0.06)	4.96 (0.001)	-1.35 (<0.0001)
Interaction				
Sex*Incubation	-0.02 (0.74)	-0.2 (0.11)	-0.36 (0.5)	0.09 (0.34)
Sex*Pre-	-0.01 (0.92)	-0.26 (0.38)	0.07 (0.93)	0.04 (0.78)
symptomatic				
Sex*Symptomatic	-0.28 (<0.0001)	-1.31 (<0.0001)	-3.09 (0.0001)	0.43 (<0.0001)
Sex*Recovery	-0.04 (0.23)	-0.25 (0.001)	-0.96 (0.02)	0.11 (0.25)

290

291 This is the Table 2 legend. Unstandardized beta coefficients are presented, with *p*-values in

292 parentheses and in bold if lower than 0.05. Sex was coded such that positive coefficients represent

293 larger values in females.

294

295 When including age, BMI, hypertension diagnosis, medication, alcohol and drug intake, the 296 interactions between sex and phase of infection remained unchanged indicating that they cannot be

297 explained by the influence of these confounding variables (S1 Table).

#### 298

#### Sex-specific differences in algorithm's performance 299

- 300 Table 3 provides a by-sex breakdown for the algorithm's performance. Sensitivity score can be found 301 as the recall of the positive class (days with an existent SARS-CoV2 infection), while specificity is the 302 recall of the negative class (days without a SARS-CoV2 infection). The algorithm showed the same 303 precision (i.e., 92) when giving a SARS-CoV2 positive alert, across participant sex. Cross-class recall 304 was more balanced among females than males in our sample. Detecting 53% of SARS-CoV-2 positive 305 days in females, the algorithm performed less well in males (26% of SARS-CoV2 positive cases 306 detected).
- 307
- 308

This is the Table 3 Title. Performance metrics of the machine learning algorithm for female and male 309 310 participants.

311

Participant Sex	Class	Precision	Recall	F-score
All	0	12.36	68.421	19.048
	1	91.599	41.509	78.331
Female	0	12.977	60.69	20.859
	1	92.147	53.125	73.181
Male	0	10.811	80.0	15.385
	1	92.308	26.667	85.714

312

313 This is the Table 3 legend. Sensitivity score can be found as the recall of the positive class (i.e., days 314 with an existent SARS-CoV2 infection), while specificity is the recall of the negative class (i.e., days 315 without a SARS-CoV2 infection).

316

#### Sex-specific differences in antibody titres of SARS-CoV-2 Nucleocapsid 317

#### after COVID-19 infection 318

319 Antibody titres of the female and male sub-groups were not significantly different across runs.

320 Nucleocapsid antibody values in run 1 trended higher in male participants (Table 4).

321

### 322 This is the Table 4 Title. SARS-CoV-2 Nucleocapsid (N) antibody (AB) values stratified according to

323 sex.

324

Variables	Male (n = 7)	Female (n = 7)	Test statistics	Significance (p value)
SARS-CoV-2 N AB run1	32.66 (± 34.74)a	75.66 (± 46.87)a	W = 13	0.14
	Male (n = 51)	Female (n = 68)		
SARS-CoV-2 N AB run2	34.1 (1 – 183.7)b	33.4 (1.7 – 212.2)b	W = 1753	0.92
	Male (n = 62)	Female (n = 85)		
SARS-CoV-2 N AB run3	40.05 (1 - 274)	29.7 (1.4 – 234.3)	W = 2772	0.59
	Male (n = 76)	Female (n = 102)		
SARS-CoV-2 N AB run4	17.95 (1.2 - 221)	36.59 (1 – 266.4)	W = 4280	0.235

325

326 This is the Table 4 legend. data are presented as mean ± SD, or median (interquartile range).

## 327 Discussion

328

329	The presented study examined sex-specific differences in physiological parameters among 82
330	individuals with a documented SARS-CoV-2 infection. We found that male participants experienced
331	significantly larger increases in wrist skin temperature, breathing rate and heart rate as well as larger
332	decreases in heart rate variability during the symptomatic period compared to females. In one of the
333	first prospective cohort studies relying on wearable sensor technology to collect real-time continuous
334	physiological signals, we provide evidence for sex-based differential physiological responses to COVID-
335	19.

336

Considering the higher mortality and hospitalization rates observed in male COVID-19 patients [9], our 337 338 findings may reflect sex-specific biological responses to the infection. In line with previous work [16], 339 we did not observe any differences between the sexes with regards to antibody titers. However, 340 Takahashi et al. [16] observed a stronger acute T-cell response in female as compared to male COVID-341 19 patients. The poorer T-cell response in men was associated with their worse disease progression. 342 On the other hand, the authors measured higher levels of several pro-inflammatory innate immunity 343 chemokines and cytokines in men as compared to women. They thus concluded that the early phase 344 of COVID-19 is associated with key sex differences in immunological mechanisms potentially 345 accounting for the differential disease progression between women and men.

346

Given that the sex differences in physiological signals in our study are most pronounced during the symptomatic phase, we propose that they reflect the above mentioned sex-specific immunological mechanisms [33]. Inflammatory markers (e.g., cytokines) have been shown to reflect disease severity in COVID-19 [34]. As the autonomic nervous system is known to modulate inflammation [35] and the

17

examined physiological signals reflect the function of the autonomic nervous system [36], our findings
 suggest support for differential immunological responses to COVID-19 between the sexes.

353

354 Importantly, altered physiological signals such as decreased heart rate variability and increased skin 355 temperature have been proposed as prognostic markers for several disorders including cardiovascular 356 disease [37] as well as infectious diseases like COVID-19 [18,38-40]. Modern wearable technology 357 represents a unique and powerful framework to collect continuous real-time physiological data. The 358 predictive value of physiological signals combined with the reliable history of measurements provided 359 by wearables opens up new avenues to inform clinical actions and support future precision medicine 360 approaches incorporating a variety of individual factors into clinical decisions (reviewed in Mitratza et 361 al. [41]).

362

363 An important step towards precision medicine can be made by considering sex differences in modern 364 digital health solutions. Historically, women have been underrepresented in clinical trials leading to 365 medical solutions focusing on men at the risk to women's health [42]. Many diseases differ between female and male patients with regards to the prevalence, progression or response to treatment [43]. 366 367 For example, minor stroke is more often missed in female than male [44] patients, possibly due to 368 definitions in clinical diagnosis reflecting typical manifestations in males [43]. More recently, a sex bias 369 has been recognized in modern ML solutions that are often developed and trained on male data and 370 thus result in better performance in men [45]. Therefore, in the presented work, we examined sex 371 differences in the performance of our ML algorithm for early detection of COVID-19. The algorithm 372 reached a higher sensitivity for female participants. We postulate this difference may be due to the

373 larger sample size in the female group. However, the algorithm's precision was the same in both374 groups indicating that it is suitable for use in both men and women, as intended.

### 375 Limitations

376 While our study belongs to the first research to consider sex-based differences in COVID-19 377 detection using digital health, future work could continue to build upon our findings by examining 378 the casual mechanism underlying differences between SARS-Cov-2 infected men and women. In 379 particular, inability to disentangle immunological versus menstrual-driven changes in physiological 380 parameters among female participants limits our research's generalizability. In menstruating 381 women, a specific pattern has been recognized in the trajectory of physiological signals across the 382 menstrual cycle. Goodale et al. have demonstrated increased skin temperature, heart rate and 383 breathing rate in the postovulatory phase of the cycle, mirroring cycle-based shifts in sex hormones 384 [26]. Sex differences in physiological signals measured in the current study may thus partly be due to 385 hormonal impact. We cannot exclude such influence as we had limited information about female 386 participants' menstrual cycle or reproductive health (e.g., usage of hormonal birth control, 387 menopausal status). Future researchers may wish to record participants' menstrual status and 388 measure hormone levels directly, to probe the relationship between sex hormones and physiological 389 differences.

390

391 Nevertheless, we believe that menses-driven changes in physiology do not adequately explain the sex 392 differences in our results, as the dynamics of the observed physiological signals are in line with 393 previous reports regarding COVID-19 and include increased skin temperature, heart rate and 394 breathing rate as well as decreased heart rate variability during infection [20]. Furthermore, the most 395 pronounced sex differences in our study occurred during the symptomatic period, suggesting a 396 disease-triggered disparity among males and females. Moreover, we do not expect that the 397 distribution of menstrual cycle phases follows a specific pattern for our participants. We rather expect 398 it to be random, and thus the hormonal effects to be cancelled out. Finally, 30% (n=17) of females in

the sample were older than 45 years; peri- or post-menopausal, they were beyond reproductive age
and thus unlikely to experience menses-modulating effects on their physiological parameters.

401

Another limitation important to note is the potential effect of recall bias on our findings. The COVID-402 403 19 symptom onset date was determined based on the participants' retrospective reports, and the 404 classification of the relevant infection periods (i.e., incubation, pre-symptomatic and symptomatic 405 period) was based on this date. Therefore, an unreliable report would be associated with an inaccurate 406 definition of the infection periods leading to shifts in trajectories of physiological signals. Furthermore, 407 in the effort to smooth the data in the model, the abrupt changes in physiological signals after 408 infection generated gradual alterations in the estimated trajectory. The deviations from the baseline 409 during the first and last days may be reflective of such model artifacts (Fig 3). Finally, it is important to 410 note that we did not adjust any parameters from our statistical tests to account for multiple testing. 411 Therefore, we acknowledge chances for type 1 error in our findings. Nevertheless, we believe that our 412 research provides important initial insights to be confirmed in future investigations.

413

## 414 Conclusion

For the first time, we show sex differences in physiological responses to COVID-19. Our results highlight the importance of taking sex into account in medical treatment and care of COVID-19 patients, as well as when validating infection detection algorithms in digital health. Moreover, we reveal the potential of continuous real-time physiological signals as a clinical tool to inform future precision medicine approaches.

420

421

422

423

## 424 Acknowledgements

425 We thank the GAPP participants who enrolled in this study. Additionally, the authors thank the following for their contributions to the study: The local study team in Vaduz, FL, the different teams 426 at the Dr Risch medical laboratories in Vaduz and Buchs, CH. We would also like to thank the Coobx 427 428 AG in Balzers, FL, for the provision of 3D printed bracelet extensions for persons with large wrists. 429 Addressing data protection issues, we acknowledge the substantial collaborative support of the Elleta 430 AG as well as the national data protection agency in Liechtenstein. We thank the government of the 431 Principality of Liechtenstein, the health ministers, and the Liechtenstein Office of Public Health for 432 their support. Finally, our thanks are especially due to the Princely House of Liechtenstein, which gave 433 decisive support that enabled the initiation of this project.

434

## 436 **References**

- 437 1. WHO. WHO. Director-General's opening remarks at the media briefing on COVID-19.
- 438 Available: https://www.who.int/dg/speeches/detail/whodirector- general-s-opening-
- 439 remarks-at-the-media-briefing-on-covid-19--- 11-march-2020
- 440 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
- 441 Pneumonia in China, 2019. N Engl J Med. 2020;382: 727–733. doi:10.1056/nejmoa2001017
- 442 3. WHO. WHO\_weekly-operational-update-on-covid-19---29-march-2021. 2021 [cited 30 Mar
- 443 2021] p. https://www.who.int/publications/m/item/weekly-ope. Available:
- 444 https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---29-
- 445 march-2021
- 446 4. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med J
- 447 R Coll Physicians London. 2020;20: 124–127. doi:10.7861/clinmed.2019-coron
- 5. Bhopal R. Covid-19 worldwide: We need precise data by age group and sex urgently. BMJ.
- 449 2020;369: 32188598. doi:10.1136/bmj.m1366
- 450 6. Health E for public, Sanità IS di. Gender differences in COVID-19: the importance of sex-
- 451 disaggregated data. Available: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-
- 452 gender-differences-importance-sex-disaggregated-data
- 453 7. Risch M, Grossmann K, Aeschbacher S, Weideli OC, Kovac M, Pereira F, et al. Investigation of
- 454 the use of a sensor bracelet for the presymptomatic detection of changes in physiological
- 455 parameters related to COVID-19: an interim analysis of a prospective cohort study (COVI-
- 456 GAPP). BMJ Open. 2022;12: e058274. doi:10.1136/bmjopen-2021-058274
- 457 8. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male
- 458 sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission.
- 459 Nat Commun. 2020;11: 1–10. doi:10.1038/s41467-020-19741-6
- 460 9. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated

461 with COVID-19-related death using OpenSAFELY. Nature. 2020;584: 430–436.

462 doi:10.1038/s41586-020-2521-4

- 463 10. Vikse J, Lippi G, Henry BM. Do sex-specific immunobiological factors and differences in
- 464 angiotensin converting enzyme 2 (ACE2) expression explain increased severity and mortality
- 465 of COVID-19 in males? Diagnosis (Berlin, Ger. 2020;7: 385–386. doi:10.1515/dx-2020-0054
- 466 11. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender
- 467 on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11: 29. doi:10.1186/s13293-020-
- 468 00304-9
- 469 12. Aggarwal NR, Patel HN, Mehta LS, Sanghani RM, Lundberg GP, Lewis SJ, et al. Sex Differences
- 470 in Ischemic Heart Disease: Advances, Obstacles, and Next Steps. Circ Cardiovasc Qual
- 471 Outcomes. 2018;11: 1–14. doi:10.1161/CIRCOUTCOMES.117.004437
- 472 13. Jacobsen H, Klein SL. Sex Differences in Immunity to Viral Infections . Frontiers in
- 473 Immunology . 2021. p. 3483. Available:
- 474 https://www.frontiersin.org/article/10.3389/fimmu.2021.720952
- 475 14. Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun Rev. 2012;11: A486-92.
- 476 doi:10.1016/j.autrev.2011.11.023
- 477 15. Kovacevic V, Markovic A, Veen D, Brakenhoff TB, Mitratza M, Goodale BM. Menstrual Cycle
- 478 Influence on COVID-19 Detection Using Machine Learning and a Wearable Medical Device
- 479 [A120]. Obstet Gynecol. 2022;139. Available:
- 480 https://journals.lww.com/greenjournal/Fulltext/2022/05001/Menstrual\_Cycle\_Influence\_on
- 481 \_COVID\_19\_Detection.118.aspx
- 482 16. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in
- immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588: 315–320.
- 484 doi:10.1038/s41586-020-2700-3
- 485 17. Bogu GK, Snyder MP. Deep learning-based detection of COVID-19 using wearables data.
- 486 medRxiv. 2021; 2021.01.08.21249474. Available:

- 487 http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249474.abstract
- 488 18. Mishra T, Wang M, Metwally AA, Bogu GK, Brooks AW, Bahmani A, et al. Pre-symptomatic
- detection of COVID-19 from smartwatch data. Nat Biomed Eng. 2020;4: 1208–1220.
- 490 doi:10.1038/s41551-020-00640-6
- 491 19. Brakenhoff TB, Franks B, Goodale BM, van de Wijgert J, Montes S, Veen D, et al. A
- 492 prospective, randomized, single-blinded, crossover trial to investigate the effect of a
- 493 wearable device in addition to a daily symptom diary for the remote early detection of SARS-
- 494 CoV-2 infections (COVID-RED): a structured summary of a study protocol fo. Trials. 2021;22:
- 495 1–5. doi:10.1186/s13063-021-05241-5
- 496 20. Quer G, Radin JM, Gadaleta M, Baca-Motes K, Ariniello L, Ramos E, et al. Wearable sensor
- data and self-reported symptoms for COVID-19 detection. Nat Med. 2021;27: 73–77.
- 498 doi:10.1038/s41591-020-1123-x
- 499 21. Ates HC, Yetisen AK, Güder F, Dincer C. Wearable devices for the detection of COVID-19. Nat
  500 Electron. 2021;4: 13–14. doi:10.1038/s41928-020-00533-1
- 501 22. Cosoli G, Scalise L, Poli A, Spinsante S. Wearable devices as a valid support for diagnostic
- 502 excellence: lessons from a pandemic going forward. Health Technol (Berl). 2021;11: 673–675.
- 503 doi:10.1007/s12553-021-00540-y
- 23. Risch L, Conen D, Aeschbacher S, Grossmann K RM. Defining the role of a fertility bracelet for
- 505 early recognition and monitoring of COVID-19 in Liechtenstein: an observational study (COVI-

506 GAPP). In: 10. April 2020. p. https://doi.org/10.1186/ISRCTN51255782.

- 507 24. Hamvas G, Hofmann A, Sakalidis V, Goodale B, Shilaih M, Leeners B. Innovative Trial Design
- 508 Using Digital Approaches: An Example From Reproductive Medicine [211]. Obstet Gynecol.
- 509 2020;135. Available:
- 510 https://journals.lww.com/greenjournal/Fulltext/2020/05001/Innovative\_Trial\_Design\_Using\_
- 511 Digital\_Approaches\_.338.aspx
- 512 25. Conen D, Schön T, Aeschbacher S, Paré G, Frehner W, Risch M, et al. Genetic and phenotypic

- 513 determinants of blood pressure and other cardiovascular risk factors: Methodology of a
- 514 prospective, population-based cohort study. Swiss Med Wkly. 2013;143: 1–9.
- 515 doi:10.4414/smw.2013.13728
- 516 26. Goodale BM, Shilaih M, Falco L, Dammeier F, Hamvas G, Leeners B. Wearable sensors reveal
- 517 menses-driven changes in physiology and enable prediction of the fertile window:
- 518 Observational study. J Med Internet Res. 2019;21. doi:10.2196/13404
- 519 27. French-Mowat E, Burnett J. How are medical devices regulated in the European Union? J R

520 Soc Med. 2012;105 Suppl: 22–28. doi:10.1258/jrsm.2012.120036

- 521 28. Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine
- 522 learning-based medical devices in the USA and Europe (2015–20): a comparative analysis.
- 523 Lancet Digit Heal. 2021;3: e195–e203. doi:10.1016/S2589-7500(20)30292-2
- 524 29. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The
- 525 global burden of disease attributable to alcohol and drug use in 195 countries and territories,
- 526 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet

527 Psychiatry. 2018;5: 987–1012. doi:10.1016/S2215-0366(18)30337-7

- 528 30. Risch M, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, et al. Temporal course of
- 529 SARS-CoV-2 antibody positivity in patients with COVID-19 following the first clinical

530 presentation. medRxiv. 2020;2020. doi:10.1101/2020.10.17.20214445

- 531 31. R Core Team (2021). The R Project for Statistical Computing. Vienna. Austria: R Foundation
  532 for Statistical Computing.; Available: https://www.r-project.org/
- 533 32. Van Rossum, G., & Drake FL. Python 3 Reference Manual. Scotts Valley, CA: CreateSpace.;
  534 2009.
- 535 33. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on
- 536 immune responses. Cell Death Differ. 2020;27: 1451–1454. doi:10.1038/s41418-020-0530-3
- 537 34. Junqueira C, Crespo Â, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, et al. FcγR-
- 538 mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606:

539 576–584. doi:10.1038/s41586-022-04702-4

- 540 35. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev
- 541 Immunol. 2002;20: 125–163. doi:10.1146/annurev.immunol.20.082401.104914
- 542 36. Ernst G. Heart-Rate Variability-More than Heart Beats? Front public Heal. 2017;5: 240.
- 543 doi:10.3389/fpubh.2017.00240
- 544 37. Papaioannou V, Pneumatikos I, Maglaveras N. Association of heart rate variability and
- 545 inflammatory response in patients with cardiovascular diseases: current strengths and
- 546 limitations. Front Physiol. 2013;4: 174. doi:10.3389/fphys.2013.00174
- 547 38. Natarajan A, Su HW, Heneghan C, Blunt L, O'Connor C, Niehaus L. Measurement of
- 548 respiratory rate using wearable devices and applications to COVID-19 detection. npj Digit
- 549 Med. 2021;4. doi:10.1038/s41746-021-00493-6
- 39. Robert P Hirten, MD, Matteo Danieletto, PhD, [...], and Zahi A Fayad P. Use of Physiological
- 551 Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict
- 552 COVID-19 Diagnosis: Observational Study. J Med Internet Res. 2021;
- 553 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC79015.
- 40. Conroy B, Silva I, Mehraei G, Damiano R, Gross B, Salvati E, et al. Real-time infection
- 555 prediction with wearable physiological monitoring and AI to aid military workforce readiness
- 556 during COVID-19. Sci Rep. 2022;12: 3797. doi:10.1038/s41598-022-07764-6
- 557 41. Marianna Mitratza, MD, PhD Ms, Brianna Mae Goodale P, Aizhan Shagadatova Ms, Vladimir
- 558 Kovacevic P, Janneke van de Wijgert, MD, PhD M, Timo B. Brakenhoff P, et al. The
- 559 Performance of Wearable Sensors in the Detection of SARS-CoV-2 infection: A Systematic
- 560Review. Lancet Digit Heal. 2022.
- 561 42. Shaw LJ, Pepine CJ, Xie J, Mehta PK, Morris AA, Dickert NW, et al. Quality and Equitable
- 562 Health Care Gaps for Women: Attributions to Sex Differences in Cardiovascular Medicine. J
- 563 Am Coll Cardiol. 2017;70: 373–388. doi:10.1016/j.jacc.2017.05.051
- 43. Schumacher Dimech A, Ferretti MT, Sandset EC, Santuccione Chadha A. The role of sex and

565	gender differences in	precision medicine: the work of the	Women's Brain Project. Eur Heart J.
-----	-----------------------	-------------------------------------	-------------------------------------

- 566 2021;42: 3215–3217. doi:10.1093/eurheartj/ehab297
- 567 44. Yu AYX, Hill MD, Asdaghi N, Boulanger J-M, Camden M-C, Campbell BC V, et al. Sex
- 568 Differences in Diagnosis and Diagnostic Revision of Suspected Minor Cerebral Ischemic
- 569 Events. Neurology. 2021;96: e732–e739. doi:10.1212/WNL.000000000011212
- 570 45. Cirillo D, Catuara-Solarz S, Morey C, Guney E, Subirats L, Mellino S, et al. Sex and gender
- 571 differences and biases in artificial intelligence for biomedicine and healthcare. npj Digit Med.
- 572 2020;3: 81. doi:10.1038/s41746-020-0288-5

## 591 Supporting information

592	S1 Table. This is the S1 Table Title. Results from multilevel linear mixed models showing the main
593	effects of infection phase, sex, age, medication, drug and alcohol intake, BMI and hypertension as
594	well as interactions between sex and infection phase with regards to changes in physiological
595	signals.
596	This is the S1 Table legend. Unstandardized beta coefficients are presented, with p-values in
597	parentheses and in bold if lower than 0.05. Sex was coded such that positive coefficients represent
598	larger values in females. Hypertension was a binary variable representing diagnosed hypertension. In
599	addition to significant effects of infection phase and sex described in the main text, we observed a
600	significant main effect of medication and alcohol intake on physiological signals. Nevertheless, these
601	effects did not alter any of the multilevel model results reported in the main text.
602	
603	
604	
605	
606	
607	
608	
609	
610	
611	
612	
613	
614	
615	

## 616 CRediT Statement for Authorship

- 617 All authors critically reviewed and approved the final version of this manuscript and had final 618 responsibility for the decision to submit for publication.
- 619 Conceptualization: MRi, HR, RT, PK, TB, BF, MM, GD, AD, SM, MC, DEG, DC and BMG, LR; Data curation:
- 620 KG, SA, MRo., VK, AM, and BMG; Formal analysis: MRi, KG, NW, OCW, MRo, DL, VK, AM, and BMG;
- 621 Funding acquisition: MRi, MC, DEG, DC and LR; Investigation: KG, SA, OCW and MM; Methodology:
- 622 MRi, AM, VK, KG, PK, TB, BF, GD, SM, MC, DEG, DC, BMG, and LR; Project administration: KG, OCW,
- 623 SM, MC and DEG; Resources: MRi, KG, SA, OCW, MK, NW, CR, DH and TL; Supervision: MRi, SA, HR,
- 624 RT, MC, DEG, DC, BMG, LR; Validation: KG, AM, NW, OCW, CR, DH, MRo, DL, VK and BMG;
- 625 Visualization: KG, AM and FP; Writing original draft: MRi, KG, AM, FP, MC, DC, BMG, LR; Writing –
- 626 review & editing: MRi, KG, AM, SA, OCW, LV, MK, FP, NW, CR, DH, TL, HR, RT, MRo, DL, PK, TB, BF,
- 627 MM, GD, AD, SM, MC, DEG, DC, BMG, LR
- 628

## 629 Declaration of Conflicts of Interest

Lorenz Risch, and Martin Risch are key shareholders of the Dr Risch Medical Laboratory. David Conen
has received consulting fees from Roche Diagnostics, outside of the current work. Andjela Markovic,
Vladimir Kovacevic and Brianna Goodale are past employees of Ava AG. Billy Franks is a former
employee of the Julius Clinic and now employee of Haleon. The other authors have no financial or
personal conflicts of interest to declare.

635

## 636 Data Sharing Statement

Anonymized data that underlie the results reported in this article are available upon justified requestto the corresponding author.

А



Tod		FF	FRI, JUL 31				
26	27	28	29	30	31	1	
	Medica	ation					
8	Oral te	mpera	ture				
-	COVID	-19 Sy	mptom	s			
	Chills						
	Diarrhea	1					
	Dry cou	gh					
	Fatigue						
	Fever						
	Loss of	smell					
	Loss of	taste					
	Muscle	or body	aches				
	Nasal co	ongestic	on or ru	nny nos	e		
	Shortne	ss of br	eath or	difficul	ty breati	ning	
	Sore thr	oat					
	Vomitin	g					

в

Fig\_1



Fig\_2



# Fig\_3